Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of vorinostat to preparation of lung cancer treatment drug

A technology of vorinostat and drugs, applied in the field of biopharmaceuticals, can solve the problems of lung cancer safety and effectiveness, adverse reactions of lung cancer, difficult popularization and application, etc., achieve good development prospects, inhibit tumor cell growth, and facilitate supervision Effect

Inactive Publication Date: 2017-11-17
FOSHAN MATERNAL & CHILD HEALTH CARE HOSPITAL
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In view of the deficiencies of the above-mentioned prior art, the object of the present invention is to provide the application of vorinostat in the preparation of a drug for the treatment of lung cancer, aiming to solve the problem that the treatment of lung cancer by surgery and chemotherapy in the prior art is likely to cause adverse reactions, The recurrence rate is high; the safety and effectiveness of tumor cell immunotherapy for lung cancer need to be improved, and the price is high, making it difficult to popularize and apply technical problems

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of vorinostat to preparation of lung cancer treatment drug
  • Application of vorinostat to preparation of lung cancer treatment drug
  • Application of vorinostat to preparation of lung cancer treatment drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027]Embodiment 1 The preparation of vorinostat solution

[0028] Vorinostat was purchased from Sigma-aldrich Company, CAS registration number: 329825127.

[0029] DMSO (dimethyl sulfoxide) was purchased from Singma-aldrich Company.

[0030] Vorinostat was prepared into a 100mM solution with dimethyl sulfoxide, and diluted to the required concentration with PBS (phosphate buffer saline) before use in cell experiments; in animal experiments, directly weigh 0.04g of vorinostat solution Prepare a 40mg / mL solution in 1mLDMSO, then take 100µl of the above 40mg / mL vorinostat solution and dilute it with 10mL of PBS to prepare a 4mg / mL vorinostat solution for use.

Embodiment 2

[0031] Example 2 The inhibitory effect of vorinostat on the proliferation of A549 and H226 cells

[0032] The human non-small cell lung cancer cell line A549 (purchased from the China Atypical Collection Center) and the human lung squamous cell carcinoma cell line H226 (purchased from the China Atypical Collection Center) in the logarithmic growth phase were used at 1000-2000 The density of cells / well was seeded in a 96-well plate, and after 24 hours, it was replaced with different concentrations of ) Vorinostat’s complete medium was used to treat the cells for 72 hours, and the cell proliferation was detected by the CCK-8 method (cell activity toxicity detection method). For the detection method, see "Medical Immunology Experimental Technology" (Soochow University Press, publication date: February 2011).

[0033] Such as figure 1 As shown, as the concentration increases, the IC50 (half maximal inhibitory concentration, half inhibitory concentration) value of vorinostat inhi...

Embodiment 3

[0034] Example 3 Vorinostat promotes the expression of MICA mRNA in A549 and H226 cells

[0035] 1. Trizol method to extract cellular RNA:

[0036] (1) A549 and H226 cells in the logarithmic growth phase (purchased from China Atypical Collection Center) were treated with concentrations of 0 μM, 0.5 μM, 1.0 μM, 1.5 μM, 2.0 μM, 5 μM, 10 μM, 15 μM, 20 μM vorinostat solution for 72h and 10 μM vorinostat for 0h, 24h, 48h, and 72h;

[0037] (2) Then wash the above-mentioned A549 and H226 cells treated with vorinostat solution twice with PBS (centrifuge at 2000rpm for 5min), then add 1mL Trizol reagent, shake slightly, and pipette evenly to ensure that the lysate is evenly distributed on the cell surface;

[0038] (3) Transfer the above-mentioned lysate containing cells to a 1.5mL EP tube (centrifuge tube), pipette repeatedly with a pipette until the lysate is fully lysed without obvious precipitation, and then stand at room temperature for 5 minutes;

[0039] (4) Add 200 μL of chl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of vorinostat to preparation of a lung cancer treatment drug. The drug is applied to treatment of non-small cell lung cancer, and can directly activate expression of MHCI-associated protein MICA on surfaces of tumor cells, improve killing abilities of NK cells for lung cancer cell strains and inhibit growth of tumor cells. Compared with the chemotherapeutic drugs extensively used in lung cancer treatment, the drug has small side effects; the drug is easy to quantify and standardize, safety, effectiveness, bioactive constituents and the like can be analyzed with conventional detection means, supervision is facilitated, high product cost caused by high detection cost is avoided, and good development prospect is realized.

Description

technical field [0001] The invention relates to the technical field of biopharmaceuticals, in particular to the application of vorinostat in the preparation of medicines for treating lung cancer. Background technique [0002] Lung cancer is one of the malignant tumors with the highest incidence in the world, and it is also the main cause of death from malignant tumors (see literature Sundar R, Soong R, Cho BC, et al. Immunotherapy in the treatment of non-small cell lung cancer[J]. Lung Cancer, 2014, 85(2): 101-9.). 85% of lung cancers are non-small cell lung cancers. Due to the lack of specific clinical manifestations of lung cancer, most patients are already in the middle and advanced stages when they are diagnosed. The prognosis of lung cancer patients is poor, and its 5-year survival rate is only 16.6%, and the 5-year survival rate of lung cancer patients with distant metastasis is only 3.9% (see literature Domingues D, Turner A, Silva MD, et al. Immunotherapy and lung ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/167A61P35/00A61P11/00
CPCA61K31/167
Inventor 夏承来
Owner FOSHAN MATERNAL & CHILD HEALTH CARE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com